USFDAAug 7, 2026, 04:04 PM
NRx Pharmaceuticals to Host Call on FDA Ketamine ANDA Review
AI Summary
NRx Pharmaceuticals, Inc. announced it will host a conference call and Q&A session on Monday, August 10, 2026, at 8:30 a.m. Eastern Time. The call will discuss the FDA's completion of the first-cycle review of the Company's Abbreviated New Drug Application (ANDA) for preservative-free ketamine, which was announced earlier today. Key management, including the CEO, CCO, and a Director, will participate to cover the regulatory path to approval and commercial plans. A live webcast and telephone dial-in options will be available for participants.
Key Highlights
- NRx Pharmaceuticals will host a conference call on Monday, August 10, 2026, at 8:30 a.m. Eastern Time.
- The call will discuss the FDA's completion of the first-cycle review of the Company's ANDA for preservative-free ketamine.
- Participating on the call will be CEO Jonathan Javitt, CCO Glenn Tyson, and Director Chaim Hurvitz.
- The discussion will cover the regulatory path to approval and the Company's commercial plans.
- A live webcast will be available on the Company’s investor relations website.
- Participants can access the call via telephone domestically at 1-800-864-5102 or internationally at 1-646-394-9810.
- A replay of the webcast will be available on the Company’s website after the event.
Price Impact
More from NRXP